![Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update | SpringerLink Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40262-019-00774-0/MediaObjects/40262_2019_774_Fig3_HTML.png)
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update | SpringerLink
![An Integrated BioSci Research On Gilead Sciences - Why The Sovaldi China Expansion Will Deliver Gargantuan Growth? (NASDAQ:GILD) | Seeking Alpha An Integrated BioSci Research On Gilead Sciences - Why The Sovaldi China Expansion Will Deliver Gargantuan Growth? (NASDAQ:GILD) | Seeking Alpha](https://static.seekingalpha.com/uploads/2017/11/30/saupload_vQmzxOwHu7LIJjY76UlvGLMbIDM0jQekxbTlXnUivBpUpUrFaKR5CjKM1TyZC_LoAAFjybT6RB6GPkIlCG48XEL5nbiux-crrvHde9x9PRIst9WJMetDp2FFOu2qAiha6TdTKJmG.png)
An Integrated BioSci Research On Gilead Sciences - Why The Sovaldi China Expansion Will Deliver Gargantuan Growth? (NASDAQ:GILD) | Seeking Alpha
![Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels - ScienceDirect Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0092867422013708-fx1.jpg)
Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels - ScienceDirect
![Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0244-1/MediaObjects/41416_2018_244_Fig1_HTML.png)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study | British Journal of Cancer
![Sofosbuvir and daclatasvir - Hessel - 2016 - British Journal of Clinical Pharmacology - Wiley Online Library Sofosbuvir and daclatasvir - Hessel - 2016 - British Journal of Clinical Pharmacology - Wiley Online Library](https://bpspubs.onlinelibrary.wiley.com/cms/asset/df8ba603-0db3-4d37-80a6-0ce5b63130fb/bcp13011-fig-0001-m.jpg)
Sofosbuvir and daclatasvir - Hessel - 2016 - British Journal of Clinical Pharmacology - Wiley Online Library
![Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity” - American Journal of Transplantation Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity” - American Journal of Transplantation](https://www.amjtransplant.org/cms/attachment/043b74ea-68d4-4150-ac47-8aca0557f04e/gr1_lrg.jpg)
Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity” - American Journal of Transplantation
![Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus - Summers - 2014 - Journal of Pharmacy and Pharmacology - Wiley Online Library Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus - Summers - 2014 - Journal of Pharmacy and Pharmacology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cfb6dd6e-a858-40b8-8fd0-52bfcd8b2a68/jphp12294-fig-0001-m.jpg)